The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Open accessAbstract
Purpose: Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors. Patients and Methods: Patients enrolled to intermittent dosing cohorts received navitoclax on day −3, followed by dosing on days 1 to 14 of a 21-day cycle. Patients on continuous dosing received a 1-week lead-in dose of 150 mg followed by continuous daily administration. Blood samples were collected for pharmacokinetic analyses, biomarker analyses, and platelet monitoring. Results: Forty-seven patients, including 29 with small-cell lung cancer (SCLC) or pulmonary carcinoid, were enrolled between 2007 and 2008, 35 on intermittent and 12 on continuous dosing cohorts. Primary toxicities included diarrhea (40%), nausea (34%), vomiting (36%), and fatigue (34%); most were grade 1 or 2. Dose- and schedule-dependent thrombocytopenia was seen in all patients. One patient with SCLC had a confirmed partial response lasting longer than 2 years, and eight patients with SCLC or carcinoid had stable disease (one remained on study for 13 months). Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes correlated with changes in tumor volume. Conclusion: Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“clinical trial data suggest that the dose-limiting toxicities of obatoclax may preclude sufficient target inhibition, in contrast to ABT-263 (30, 34, 35).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.a115.109006 · Cited by 153
RetractedPardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109006200 · Cited by 145
RetractedAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“This is a mechanism-based toxicity induced by inhibition of Bcl-xL in circulating platelets,(13,18) which is required for platelet survival.(19,20) Here we describe a phase I dose-escalation study to evaluate the safety (with particular attention to platelet dynamics), pharmacokinetics, and preliminary efficacy of nav…”
BackgroundThe role of Bcl-2 family members in tumorigenesis
Kirkin, V., Joos, S., & Zörnig, M. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.009 · Cited by 567
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., ZAHURAK, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 475
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Ben-Ezra JM, 1994, Am J Pathol, 145, 1036
- Brambilla E, 1996, Am J Pathol, 149, 1941
Cited by
Sorted by citations
Items 101–200 of 616
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
Ploumaki, I., Triantafyllou, E., Koumprentziotis, I., Karampinos, K. I., Drougkas, K., Karavolias, I., Trontzas, I. P., & Kotteas, E. A. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03070-9 · Cited by 101
Yap, J. L., Chen, L., Lanning, M. E., & Fletcher, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01888 · Cited by 99
Sarosiek, K. A., & Letai, A. G. (2016) · FEBS Journal · doi:10.1111/febs.13714 · Cited by 102
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
Alam, M., Ali, S., Mohammad, T., Hasan, G. M., Yadav, D. K., & Hassan, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910442 · Cited by 97
Hussain, M., Carducci, M. A., Slovin, S. F., Cetnar, J. P., Qian, J. X., McKeegan, E. M., Refici-Buhr, M., Chyla, B., Shepherd, S. P., Giranda, V. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0099-0 · Cited by 97
Self-citationRegulation of platelet lifespan by apoptosis
Lebois, M., & Josefsson, E. C. (2016) · Platelets · doi:10.3109/09537104.2016.1161739 · Cited by 96
Li, B., Chonghaile, T. N., Fan, Y., Madden, S. F., Klinger, R. W., O’Connor, A. E., Walsh, L., O’Hurley, G., Udupi, G. M., Joseph, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2546 · Cited by 97
Cellular and molecular biology of small cell lung cancer: an overview.
Karachaliou, N., Pilotto, S., Lazzari, C., Bria, E., de Marinis, F., & Rosell, R. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.02 · Cited by 96
Multipolar functions of BCL-2 proteins link energetics to apoptosis
Hardwick, J. M., Chen, Y., & Jonas, E. A. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.03.005 · Cited by 96
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
Bajwa, N., Liao, C., & Nikolovska‐Coleska, Z. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.644274 · Cited by 94
Chen, B., Wang, Z., Sun, J., Song, Q., He, B., Zhang, H., Wang, X., Dai, W., & Zhang, Q. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.10.001 · Cited by 95
BCL-2 is dispensable for thrombopoiesis and platelet survival
Debrincat, M. A., Pleines, I., Lebois, M., Lane, R. M., Holmes, M. L., Corbin, J., Vandenberg, C. J., Alexander, W. S., Ng, A. P., Strasser, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.97 · Cited by 92
Functions of BCL-X L at the Interface between Cell Death and Metabolism
Michels, J., Kepp, O., Senovilla, L., Lissa, D., Castedo, M., Kroemer, G., & Galluzzi, L. (2013) · International Journal of Cell Biology · doi:10.1155/2013/705294 · Cited by 99
Khaw, S. L., Mérino, D., Anderson, M. A., Glaser, S. P., Bouillet, P., Roberts, A. W., & Huang, D. C. S. (2014) · Leukemia · doi:10.1038/leu.2014.1 · Cited by 93
Weeden, C. E., Ah-Cann, C., Holik, A. Z., Pasquet, J., Garnier, J.-M., Mérino, D., Lessène, G., & Asselin-Labat, M.-L. (2018) · Oncogene · doi:10.1038/s41388-018-0268-2 · Cited by 90
Tolcher, A. W., Rodrigueza, W. V., Rasco, D. W., Patnaik, A., Papadopoulos, K. P., Amaya, A., Moore, T. D., Gaylor, S. K., Bisgaier, C. L., Sooch, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2361-0 · Cited by 89
Rooswinkel, R. W., van de Kooij, B., Verheij, M., & Borst, J. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.109 · Cited by 87
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
Tan, D. S. P., Miller, R. E., & Kaye, S. B. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.126 · Cited by 88
Interventions for age-related diseases: Shifting the paradigm
Figueira, I., Fernandes, A. M. A., Mladenović, A., Lopez-Contreras, A. J., Henriques, C. M., Selman, C., Ferreiro, E. B., Gonos, E. S., Trejo, J. L., Misra, J., et al. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.009 · Cited by 92
Suryani, S., Carol, H., Chonghaile, T. N., Frismantas, V., Sarmah, C. K., High, L. M., Bornhauser, B. C., Cowley, M. J., Szymanska, B., Evans, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0259 · Cited by 86
Bad phosphorylation as a target of inhibition in oncology
Bui, N.-L.-C., Pandey, V., Zhu, T., Ma, L., Basappa, & Lobie, P. E. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.017 · Cited by 86
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
Wei, Y., Cao, Y., Sun, R., Cheng, L., Xiong, X., Jin, X. K., He, X., Lu, W., & Zhao, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584974 · Cited by 87
Vela, L., & Marzo, I. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.014 · Cited by 86
Nakajima, W., Hicks, M. A., Tanaka, N., Krystal, G., & Harada, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.6 · Cited by 86
Al-harbi, S., Hill, B. T., Mazumder, S., Singh, K., DeVecchio, J., Choudhary, G. S., Rybicki, L. A., Kalaycio, M. E., Maciejewski, J. P., Houghton, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340364 · Cited by 85
Apoptosis-Modulating Drugs for Improved Cancer Therapy
Ocker, M., & Höpfner, M. (2012) · European Surgical Research · doi:10.1159/000336875 · Cited by 87
Valcourt, D. M., Dang, M. N., Scully, M. A., & Day, E. S. (2020) · ACS Nano · doi:10.1021/acsnano.9b09263 · Cited by 85
Bai, L., Chen, J., McEachern, D., Liu, L., Zhou, H., Aguilar, A., & Wang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099404 · Cited by 83
Cleary, J. M., Lima, C. M. S. R., Hurwitz, H. I., Montero, A. J., Franklin, C., Yang, J., Graham, A., Busman, T., Mabry, M., Holen, K., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0110-9 · Cited by 80
Self-citationModica-Napolitano, J. S., & Weissig, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817394 · Cited by 80
Antibody-enabled small-molecule drug discovery
Lawson, A. D. G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3756 · Cited by 83
Wang, B., Ni, Z., Dai, X., Qin, L., Li, X., Xu, L., Lian, J., & He, F. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-98 · Cited by 83
Targeting Cancer Cell Mitochondria as a Therapeutic Approach: Recent Updates
Cui, Q., Wen, S., & Huang, P. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0011 · Cited by 83
Tamaki, H., Harashima, N., Hiraki, M., Arichi, N., Nishimura, N., Shiina, H., Naora, K., & Harada, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2550 · Cited by 79
Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
Goldsmith, K. C., Gross, M., Peirce, S. K., Luyindula, D., Liu, X., Vu, A. T., Sliozberg, M., Guo, R. J., Zhao, H., Reynolds, C. P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3603 · Cited by 79
Tan, N., Wong, M., Nannini, M., Hong, R., Lee, L. B., Price, S., Williams, K. R., Savy, P., Yue, P., Sampath, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0949 · Cited by 80
Pareja, F. G., Macleod, D., Shu, C., Crary, J. F., Canoll, P., Ross, A. H., & Siegelin, M. D. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0650 · Cited by 80
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Inao, T., Iida, Y., Moritani, T., Okimoto, T., Tanino, R., Kotani, H., & Harada, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25370 · Cited by 79
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
Winter, P. S., Sarosiek, K. A., Lin, K., Meggendorfer, M., Schnittger, S., Letai, A. G., & Wood, K. C. (2014) · Science Signaling · doi:10.1126/scisignal.2005301 · Cited by 78
Hu, Y., Yagüe, E., Zhao, J., Wang, L., Bai, J., Yang, Q., Pan, T., Zhao, H., Liu, J., & Zhang, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.036 · Cited by 77
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Mukherjee, N., Skees, J., Todd, K. J., West, D. A., Lambert, K. A., Robinson, W. A., Amato, C. M., Couts, K. L., Gulick, R. J. V., MacBeth, M. L., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2646-2 · Cited by 76
Mitochondria: The metabolic switch of cellular oncogenic transformation
Tan, Y. Q., Zhang, X., Zhang, S., Zhu, T., Garg, M., Lobie, P. E., & Pandey, V. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188534 · Cited by 75
Balachander, S. B., Criscione, S. W., Byth, K. F., Cidado, J. R., Adam, A., Lewis, P. M., Macintyre, T., Wen, S., Lawson, D., Burke, K. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0863 · Cited by 73
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Montero, J., & Haq, R. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1334 · Cited by 75
Lindamulage, I. K. S., Vu, H.-Y. T., Karthikeyan, C., Knockleby, J., Lee, Y.-F., Trivedi, P., & Lee, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-10972-0 · Cited by 72
BCL-2: Long and winding path from discovery to therapeutic target
Schenk, R. L., Strasser, A., & Dewson, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.100 · Cited by 74
Selective targeting of antiapoptotic BCL‐2 proteins in cancer
Timuçin, A. C., Başağa, H., & Kütük, Ö. (2018) · Medicinal Research Reviews · doi:10.1002/med.21516 · Cited by 73
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
Thummuri, D., Khan, S. U., Underwood, P. W., Zhang, P., Wiegand, J. S., Zhang, X., Budamagunta, V., Sobh, A., Tagmount, A., Loguinov, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0474 · Cited by 73
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
Cao, L., Li, K., Li, Q., Tong, Q., Wang, Y., & Huang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02475-8 · Cited by 79
Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 73
Rautureau, G. J. P., Yabal, M., Yang, H. J., Huang, D. C. S., Kvansakul, M., & Hinds, M. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.178 · Cited by 69
Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer.
Weyhenmeyer, B., Murphy, Á. C., Prehn, J. H. M., & Murphy, B. M. (2012) · PubMed · Cited by 68
Mizukawa, B. E., Wei, J.-P., Shrestha, M., Wunderlich, M., Chou, F., Griesinger, A. M., Harris, C. E., Kumar, A. R., Zheng, Y., Williams, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351817 · Cited by 69
Management of Small Cell Lung Cancer
Califano, R., Abidin, A. Z., Peck, R., Finn, C. F., & Lorigan, P. C. (2012) · Drugs · doi:10.2165/11597640-000000000-00000 · Cited by 68
It's time to die: BH3 mimetics in solid tumors
Kehr, S., & Vogler, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118987 · Cited by 67
Tolcher, A. W., LoRusso, P. M., Arzt, J. A., Busman, T. A., Lian, G., Rudersdorf, N. S., Vanderwal, C. A., Kirschbrown, W. P., Holen, K. D., & Rosen, L. S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2883-8 · Cited by 68
Self-citationHe, L., Torres‐Lockhart, K., Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S. M., Benes, C. H., & Ellisen, L. W. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0417 · Cited by 67
Shaw, S., Bian, Z., Zhao, B., Tarr, J. C., Veerasamy, N., Jeon, K. O., Belmar, J., Arnold, A. L., Fogarty, S. A., Perry, E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01155 · Cited by 67
Karpel‐Massler, G., Bâ, M., Shu, C., Halatsch, M., Westhoff, M., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2015) · Oncotarget · doi:10.18632/oncotarget.5505 · Cited by 68
Vlahovic, G., Karantza, V., Wang, D., Cosgrove, D., Rudersdorf, N. K., Yang, J., Xiong, H., Busman, T. A., & Mabry, M. H. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0116-3 · Cited by 66
Self-citationOvercoming multiple drug resistance mechanisms in medulloblastoma
Othman, R. T., Kimishi, I., Bradshaw, T. D., Storer, L. C. D., Korshunov, A., Pfister, S. M., Grundy, R. G., Kerr, I. D., & Coyle, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-57 · Cited by 65
Yan, X., Li, P., Zhan, Y., Qi, M., Liu, J., An, Z., Yang, W., Xiao, H., Wu, H., Qi, Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.031 · Cited by 65
Yang, Y., Jn-Simon, N., He, Y., Sun, C., Zhang, P., Hu, W., Tian, T., Zeng, H., Basha, S., Huerta, A. S., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00811-7 · Cited by 65
How to unleash mitochondrial apoptotic blockades to kill cancers?
Deng, J. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.08.005 · Cited by 65
Small Cell Lung Cancer: Therapies and Targets
Pillai, R. N., & Owonikoko, T. K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.015 · Cited by 63
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 63
Polier, G., Giaisi, M., Köhler, R., Müller, W. W., Lutz, C., Buss, E. C., Krammer, P. H., & Li‐Weber, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29009 · Cited by 61
Anti-cancer drug discovery and development
Liu, Q., & Wang, H. (2012) · Communicative & Integrative Biology · doi:10.4161/cib.21554 · Cited by 63
Scherr, M., Elder, A., Battmer, K., Barzan, D., Bomken, S. N., Ricke‐Hoch, M., Schröder, A., Venturini, L., Blair, H., Vormoor, J. H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.361 · Cited by 61
Hematologic malignancies: newer strategies to counter the BCL-2 protein
Ebrahim, A. S., Sabbagh, H., Liddane, A., Raufi, A. M., Kandouz, M., & Al-Katib, A. M. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2144-1 · Cited by 61
To Prime, or Not to Prime: That Is the QuestionPreprint
Potter, D. S., & Letai, A. G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030841 · Cited by 69
Small cell lung cancer: new clinical recommendations and current status of biomarker assessment
Planchard, D., & Pechoux, C. L. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70173-3 · Cited by 60
Molecular Cell Biology of Apoptosis and Necroptosis in Cancer
Dillon, C. P., & Green, D. R. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_1 · Cited by 62
Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
Ritter, V., Krautter, F., Klein, D., Jendrossek, V., & Rudner, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03971-7 · Cited by 59
Studying protein–protein interactions: Latest and most popular approaches
Akbarzadeh, S., Coşkun, Ö., & Günçer, B. (2024) · Journal of Structural Biology · doi:10.1016/j.jsb.2024.108118 · Cited by 60
Mcl-1 is an important therapeutic target for oral squamous cell carcinomas
Maji, S., Samal, S. K., Pattanaik, L., Panda, S., Quinn, B. A., Das, S. K., Sarkar, D., Pellecchia, M., Fisher, P. B., & Dash, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3932 · Cited by 58
Jebahi, A., Villedieu, M., Pétigny-Lechartier, C., Brotin, É., Louis, M.-H., Abeilard, E., Giffard, F., Guercio, M., Briand, M., Gauduchon, P., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.001 · Cited by 61
SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
Wu, S., Fatkhutdinov, N., Fukumoto, T., Bitler, B. G., Park, P. H., Kossenkov, A. V., Trizzino, M., Tang, H., Zhang, L., Gardini, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06656-6 · Cited by 57
Cellular Senescence as a Targetable Risk Factor for Cardiovascular Diseases
Kumar, M., Yan, P., Kuchel, G. A., & Xu, M. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.12.003 · Cited by 59
Why anti-Bcl-2 clinical trials fail: a solution
Harazono, Y., Nakajima, K., & Raz, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9450-8 · Cited by 57
Schmid, D., Jarvis, G. E., Fay, F., Small, D. M., Greene, M. K., Majkut, J., Spence, S., McLaughlin, K. M., McCloskey, K. D., Johnston, P. G., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.413 · Cited by 56
Sitia, L., Bonizzi, A., Mazzucchelli, S., Negri, S., Sottani, C., Grignani, E., Rizzuto, M. A., Prosperi, D., Sorrentino, L., Morasso, C., et al. (2021) · Cells · doi:10.3390/cells10020328 · Cited by 56
Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members
Hosseini, A., Espona‐Fiedler, M., Soto‐Cerrato, V., Quesada, R., Pérez‐Tomás, R., & Guallar, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057562 · Cited by 55
Tang, Z.-H., Jiang, X., Guo, X., Fong, C. M. V., Chen, X., & Lu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13150 · Cited by 56
Iksen, I., Witayateeraporn, W., Hardianti, B., & Pongrakhananon, V. (2024) · Phytotherapy Research · doi:10.1002/ptr.8157 · Cited by 57
Targeting the Apoptosis Pathway in Prostate Cancer
Zielinski, R., Eigl, B. J., & Chi, K. N. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e3182801cf7 · Cited by 54
Nguyen, Q., Lavdas, I., Gubbins, J., Smith, G. S. T., Fortt, R., Carroll, L. S., Graham, M. A., & Aboagye, E. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3814 · Cited by 54
Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
Gardner, E. E., Connis, N., Poirier, J. T., Cope, L., Dobromilskaya, I., Gallia, G. L., Rudin, C. M., & Hann, C. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3460 · Cited by 54
Self-citationTouzeau, C., Dousset, C., Bodet, L., Gomez‐Bougie, P., Bonnaud, S., Moreau, A., Moreau, P., Pellat‐Deceunynck, C., Amiot, M., & Gouill, S. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0955 · Cited by 54
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
Dou, Z., Zhao, D., Chen, X., Xu, C., Jin, X., Zhang, X., Wang, Y., Xie, X., Li, Q., Di, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02001-w · Cited by 56
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 56
Karpel‐Massler, G., Shu, C., Chau, L., Banu, M. A., Halatsch, M., Westhoff, M., Ramirez, Y. P., Ross, A. H., Bruce, J. N., Canoll, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3993 · Cited by 53
Vitamin K2 Covalently Binds to Bak and Induces Bak-Mediated Apoptosis
Karasawa, S., Azuma, M., Kasama, T., Sakamoto, S., Kabe, Y., Imai, T., Yamaguchi, Y., Miyazawa, K., & Handa, H. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082602 · Cited by 53
Wali, V. B., Langdon, C. G., Held, M. A., Platt, J. T., Patwardhan, G. A., Safonov, A. M., Aktaş, B., Pusztai, L., Stern, D. F., & Hatzis, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1901 · Cited by 53
Chen, P., Kuang, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., Feng, Y. Y., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-547 · Cited by 52
Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Lafontaine, J., Cardin, G. B., Malaquin, N., Boisvert, J.-S., Rodier, F., & Wong, P. (2021) · Cancers · doi:10.3390/cancers13030386 · Cited by 54
Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration
Wu, Y., Shen, S., Shi, Y., Tian, N., Zhou, Y., & Zhang, X. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.823945 · Cited by 53
Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds
Choudhary, N., Bawari, S., Burcher, J. T., Sinha, D., Tewari, D., & Bishayee, A. (2023) · Cancers · doi:10.3390/cancers15153980 · Cited by 56
Anderson, N. M., Harrold, I., Mansour, M. R., Sanda, T., McKeown, M. R., Nagykary, N., Bradner, J. E., Zhang, G. L., Look, A. T., & Feng, H. (2013) · Leukemia · doi:10.1038/leu.2013.377 · Cited by 52
Metadata
- Authors
- Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., Dive, C., Enschede, S. H., Nolan, C., Chiu, Y.-L., Busman, T., Xiong, H., Krivoshik, A. P., Humerickhouse, R., Shapiro, G. I., & Rudin, C. M.
- Affiliations
- Rush University Medical Center (US)
- From the Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Northwest Medical Specialties, Tacoma, WA; Rush University Medical Center, Chicago; Abbott Laboratories, Abbott Park, IL; University of California Davis Cancer Center, Sacramento, CA; Sunterra Oncology Associates, Phoenix, AZ; Johns Hopkins University, Baltimore, MD; and Paterson Institute for Cancer Research, University of Manchester, United Kingdom.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 909-916
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4668282
- OpenAlex
- W2119316461
- Cited by
- 603
- References
- 39
- Citations by year
- 2026: 35 · 2025: 28 · 2024: 30 · 2023: 34 · 2022: 32 · 2021: 37 · 2020: 39 · 2019: 29 · 2018: 33 · 2017: 31 · 2016: 40 · 2015: 46 · 2014: 57 · 2013: 54 · 2012: 51
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- navitoclax, BCL-2 inhibitor, small cell lung cancer, bronchial carcinoid, thrombocytopenia, progastrin-releasing peptide, apoptosis resistance, pharmacokinetics, safety and tolerability, intermittent dosing, continuous dosing, surrogate markers
- MeSH terms
- Administration, Oral, Aged, Aged, 80 and over, Aniline Compounds, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasms, Prognosis, Sulfonamides, Survival Analysis, Treatment Outcome, Risk Assessment, Genes, bcl-2, Maximum Tolerated Dose, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
